Sarepta Therapeutics Inc (SRPT) 21.10 $SRPT
Shares of companies testing Ebola vaccines rise
AP - 2 hrs 45 mins ago
NEW YORK (AP) — Shares of some companies that are studying potential vaccines for Ebola climbed after federal officials announced that the first case of the disease has been diagnosed in the U.S.
Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate
Business Wire - Tue Sep 30, 6:30AM CDT
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced favorable safety results from the single ascending dose portion of a Phase I study of AVI-7100, the company's lead candidate for the treatment of influenza virus, in healthy volunteers. The clinical trial is being conducted at the National Institutes of Health (NIH) through a collaboration between the company and the NIH's National Institute of Allergy and Infectious Diseases. AVI-7100 uses Sarepta's advanced and proprietary PMOplus(TM) chemistry, which is also the basis of the company's clinical-stage Ebola and Marburg drug candidates.
Biotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, Agios
at The Street - Fri Sep 26, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Sarepta Therapeutics to Present at Leerink Partners Rare Disease Roundtable
Business Wire - Wed Sep 24, 4:25PM CDT
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to participate in a fireside chat at the Leerink Partners Rare Disease Roundtable in New York on Wednesday, October 1, 2014, at 8:00 a.m. ET.
Why Sarepta Therapeutics (SRPT) Stock Is Gaining Today
at The Street - Wed Sep 24, 9:23AM CDT
Sarepta Therapeutics (SRPT) shares are up after analysts at Credit Suisse initiated coverage with a 'buy' rating on Wednesday.
Tekmira Experimental Ebola Drug Used to Treat Stricken U.S. Doctor
at The Street - Mon Sep 22, 6:48PM CDT
Ebola patient Dr. Rick Sacra received treatment with Tekmira Pharmaceuticals' experimental ebola therapy TKM-Ebola for seven days, Nebraska Medical Center confirmed.
Why Sarepta Therapeutics Inc. Stock Soared By 17% in 2014
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 17, 7:45AM CDT
If I had to place my bets I'd suggest that Sarepta Therapeutics ' shareholders must love rollercoasters, because it's been nothing but a wild ride for the clinical-stage biopharmaceutical company over the trailing year. Though shares have risen a...
George Soros Is Betting on This Risky Stock: Should You?
George Budwell, The Motley Fool - Motley Fool - Sun Sep 14, 1:03PM CDT
Source: www.theguardian.com Unlike Warren Buffett, Bill Ackman, and other classic value investors, the controversial billionaire George Soros doesn't rely solely on fundamentals to guide his investing decisions. Instead, he looks for the formation...
Ebola-Stricken Doc Receives Experimental Drug, But Which One?
at The Street - Thu Sep 11, 1:20PM CDT
Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.
Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity
at The Street - Wed Sep 10, 8:36AM CDT
The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)
Ebola Outbreak Strikes Africa: How We're Fighting Back
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 08, 12:37PM CDT
This week, the World Health Organization announced that the Ebola outbreak in West Africa has killed more than 1,900 people. This is the largest Ebola outbreak in history, with more people dying in this outbreak than all the other outbreaks since the...
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
Business Wire - Thu Aug 28, 7:00AM CDT
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to present a company overview at the following investor conferences in September. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.
The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks
at The Street - Tue Aug 26, 1:22PM CDT
It's not the hedge fund mogul you expect.
Sarepta Enters into Partnership with Flagship Biosciences to Digitally Automate the Measurement of Dystrophin, a Key Therapeutic Efficacy Marker for Muscular Dystrophy
Business Wire - Thu Aug 21, 8:00AM CDT
--Automation of dystrophin measurement will aid development of Sarepta's Duchenne muscular dystrophy candidates
Critical Alerts For Lowes, FuelCell Energy, Sarepta Therapeutics, Nuance Communications and Herbalife Released By InvestorsObserver
PR Newswire - Wed Aug 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LOW, FCEL, SRPT, NUAN and HLF.
Potential Payoffs Spur Big Board Biotech Action
ACCESSWIRE - Tue Aug 12, 2:03PM CDT
Los Angeles, CA / ACCESSWIRE / August 12, 2014 / Speculators were pushing certain big board biotechs higher as they placed their bets on potentially big future payoffs.
Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:49PM CDT
Sarepta reported second quarter loss of 85 cents per share compared to a loss of 60 cents per share in the year-ago quarter.
Tekmira Ebola Drug Hold Lifted By FDA, Stock Soars
at Investor's Business Daily - Fri Aug 08, 1:04PM CDT
Biotech firm Tekmira Pharmaceuticals vaulted more than 39% in huge volume during afternoon trading on the stock market today after the FDA partially lifted a hold on its drug candidate for treating Ebola. Tekmira's (TKMR) drug, TKM-Ebola, is in a...
Today's Dead Cat Bounce Stock Is Sarepta Therapeutics (SRPT)
at The Street - Fri Aug 08, 10:09AM CDT
Trade-Ideas LLC identified Sarepta Therapeutics (SRPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
Sarepta Therapeutics Announces Second Quarter 2014 Financial Results and Recent Corporate Developments
Business Wire - Thu Aug 07, 6:35AM CDT
--On track to submit New Drug Application for eteplirsen by year-end
Shares of companies testing Ebola vaccines rise
AP - 2 hrs 45 mins ago
NEW YORK (AP) — Shares of some companies that are studying potential vaccines for Ebola climbed after federal officials announced that the first case of the disease has been diagnosed in the U.S.
Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate
Business Wire - Tue Sep 30, 6:30AM CDT
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced favorable safety results from the single ascending dose portion of a Phase I study of AVI-7100, the company's lead candidate for the treatment of influenza virus, in healthy volunteers. The clinical trial is being conducted at the National Institutes of Health (NIH) through a collaboration between the company and the NIH's National Institute of Allergy and Infectious Diseases. AVI-7100 uses Sarepta's advanced and proprietary PMOplus(TM) chemistry, which is also the basis of the company's clinical-stage Ebola and Marburg drug candidates.
Biotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, Agios
at The Street - Fri Sep 26, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Sarepta Therapeutics to Present at Leerink Partners Rare Disease Roundtable
Business Wire - Wed Sep 24, 4:25PM CDT
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to participate in a fireside chat at the Leerink Partners Rare Disease Roundtable in New York on Wednesday, October 1, 2014, at 8:00 a.m. ET.
Why Sarepta Therapeutics (SRPT) Stock Is Gaining Today
at The Street - Wed Sep 24, 9:23AM CDT
Sarepta Therapeutics (SRPT) shares are up after analysts at Credit Suisse initiated coverage with a 'buy' rating on Wednesday.
Tekmira Experimental Ebola Drug Used to Treat Stricken U.S. Doctor
at The Street - Mon Sep 22, 6:48PM CDT
Ebola patient Dr. Rick Sacra received treatment with Tekmira Pharmaceuticals' experimental ebola therapy TKM-Ebola for seven days, Nebraska Medical Center confirmed.
Why Sarepta Therapeutics Inc. Stock Soared By 17% in 2014
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 17, 7:45AM CDT
If I had to place my bets I'd suggest that Sarepta Therapeutics ' shareholders must love rollercoasters, because it's been nothing but a wild ride for the clinical-stage biopharmaceutical company over the trailing year. Though shares have risen a...
George Soros Is Betting on This Risky Stock: Should You?
George Budwell, The Motley Fool - Motley Fool - Sun Sep 14, 1:03PM CDT
Source: www.theguardian.com Unlike Warren Buffett, Bill Ackman, and other classic value investors, the controversial billionaire George Soros doesn't rely solely on fundamentals to guide his investing decisions. Instead, he looks for the formation...
Ebola-Stricken Doc Receives Experimental Drug, But Which One?
at The Street - Thu Sep 11, 1:20PM CDT
Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.
Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity
at The Street - Wed Sep 10, 8:36AM CDT
The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)
Ebola Outbreak Strikes Africa: How We're Fighting Back
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 08, 12:37PM CDT
This week, the World Health Organization announced that the Ebola outbreak in West Africa has killed more than 1,900 people. This is the largest Ebola outbreak in history, with more people dying in this outbreak than all the other outbreaks since the...
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
Business Wire - Thu Aug 28, 7:00AM CDT
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to present a company overview at the following investor conferences in September. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.
The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks
at The Street - Tue Aug 26, 1:22PM CDT
It's not the hedge fund mogul you expect.
Sarepta Enters into Partnership with Flagship Biosciences to Digitally Automate the Measurement of Dystrophin, a Key Therapeutic Efficacy Marker for Muscular Dystrophy
Business Wire - Thu Aug 21, 8:00AM CDT
--Automation of dystrophin measurement will aid development of Sarepta's Duchenne muscular dystrophy candidates
Critical Alerts For Lowes, FuelCell Energy, Sarepta Therapeutics, Nuance Communications and Herbalife Released By InvestorsObserver
PR Newswire - Wed Aug 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LOW, FCEL, SRPT, NUAN and HLF.
Potential Payoffs Spur Big Board Biotech Action
ACCESSWIRE - Tue Aug 12, 2:03PM CDT
Los Angeles, CA / ACCESSWIRE / August 12, 2014 / Speculators were pushing certain big board biotechs higher as they placed their bets on potentially big future payoffs.
Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:49PM CDT
Sarepta reported second quarter loss of 85 cents per share compared to a loss of 60 cents per share in the year-ago quarter.
Tekmira Ebola Drug Hold Lifted By FDA, Stock Soars
at Investor's Business Daily - Fri Aug 08, 1:04PM CDT
Biotech firm Tekmira Pharmaceuticals vaulted more than 39% in huge volume during afternoon trading on the stock market today after the FDA partially lifted a hold on its drug candidate for treating Ebola. Tekmira's (TKMR) drug, TKM-Ebola, is in a...
Today's Dead Cat Bounce Stock Is Sarepta Therapeutics (SRPT)
at The Street - Fri Aug 08, 10:09AM CDT
Trade-Ideas LLC identified Sarepta Therapeutics (SRPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
Sarepta Therapeutics Announces Second Quarter 2014 Financial Results and Recent Corporate Developments
Business Wire - Thu Aug 07, 6:35AM CDT
--On track to submit New Drug Application for eteplirsen by year-end
